Class of medications
POPULARITY
29 episodes with antipsychotics
14 episodes with antipsychotics
16 episodes with antipsychotics
12 episodes with antipsychotics
13 episodes with antipsychotics
21 episodes with antipsychotics
17 episodes with antipsychotics
6 episodes with antipsychotics
5 episodes with antipsychotics
6 episodes with antipsychotics
4 episodes with antipsychotics
6 episodes with antipsychotics
10 episodes with antipsychotics
6 episodes with antipsychotics
7 episodes with antipsychotics
2 episodes with antipsychotics
3 episodes with antipsychotics
2 episodes with antipsychotics
What is the culture around prescribing antipsychotics to young people? Are there concerns around over-prescribing antipsychotics in young people? How can we reduce antipsychotics use in children and adolescents? All this and more answered as Jo Carlowe interviews Dr. Robert Penfold about the Safer Use of Antipsychotics in Youth (SUAY) pragmatic trial, as published in the JCPP.
In this episode, we discuss Autism and Education. We explore some current condition within education and some personal experiences. Specifically, the school day is in complete conflict with Autism- both Criteria A and B. This is the primary factor with the challenges of Autism in Education. The classroom requires a Social Dynamic, a Speech and Language Dynamic, and Sensory-Processing Dynamic, which is 3 strikes against Autism. In addition, the subject switching throughout the school day complicates our path of learning- Our learning style prefers spending extended times on a single subject. Autism gives us the ability to be comfortable within ourselves and this accelerates our learning, our Superpowers. School and the world mostly requires the social communication and interaction. Antipsychotics https://www.marketresearchfuture.com/reports/antipsychotic-drugs-market-2784#:~:text=The%20antipsychotic%20drugs%20market%20size,period%20(2023%20%2D%202030). Pediatrician and Psychologists on the Medical Paradigm https://podcasts.apple.com/us/podcast/radically-genuine-podcast-with-dr-roger-mcfillin/id1573253801?i=1000624733618 Autism and Education https://www.fhautism.com/shop/autism-and-education-the-way-i-see-it-what-parents-and-teachers-need-to-know/ Thinking in Pictures https://www.grandin.com/inc/visual.thinking.html Autism and Intelligence and an Explanation https://www.youtube.com/watch?v=pxNg0xcadsM&t=316s (0:00) Intro; Autism and Education; Are Educators educated on Autism?; Biases from others towards the environment (7:00) The Prescription Era; Medication first Paradigm (10:32) The School Day- Conflicts with Criteria A and B; Limits a Capacity to Think; Underlying thoughts and feelings of agitation and frustration when learning; (13:15) Autism gives us the ability to be comfortable within ourselves; Are we like the so-called normal people, or not? (13:39) The Classroom- Social Dynamic, Speech and Language Dynamic, Sensory-Processing Dynamic, 3 strikes against Autism; (14:39) Subject Switching and Criteria B conflict (17:14) If you have met one child with Autism, you have met one child with Autism (17:49) Elementary School, 2 reasons why Reading is HARD, Social dynamic experience; (23:07) 4th Grade personal experience- easy task from the outside, tremendous difficulty for Autistics; (27:00) Art was fine, other subjects were not fine; Details to General versus General to Details; (27:58) High School personal experiences; Pathway to Success ＞ General Education; (29:52) Did I graduate, or Not? (31:56) SAT (32:43) Assessment Superpowers and Superdeficits- Very Superior to Severe/Impaired; Schools simply cannot accommodate to all- within group (Autistic to Autistic) or between group (Autistic to Masses) (36:34) Education Arrangement; Taking Notes is challenging (39:16) Wrap Up, Reviews, Ratings, Feedback, Contact Information
Do Antipsychotic Meds Prevent Awakening Learn more about your ad choices. Visit megaphone.fm/adchoices
Dr. Sam Clark, Founder and CEO of Terran Biosciences, is developing a long-acting once-daily formulation of a new class of antipsychotic drugs to treat schizophrenia. The use of a prodrug approach to modify the new drug Cobenfy allows for improved bioavailability and has been shown to have fewer side effects than traditional antipsychotics. This novel class of antipsychotic drugs targets the muscarinic receptor system, which is a different mechanism of action compared to existing treatments. Sam explains, "Schizophrenia is a very severe disease. It has both hallucinations and delusions. It also has a set of symptoms called negative symptoms, which encompass social withdrawal and symptoms that can resemble depressive symptoms, cognitive dysfunction, and memory issues. So, with this patient population, there are a number of drugs that are approved to treat schizophrenia called antipsychotics. But until now, there hasn't been a new drug approved with a new mechanism. So, all drugs have the same mechanism to treat the disease since the 1950s." "But we just got, right now in the space, a new drug approved from Bristol Myers. It just got approved, and Cobenfy is the first new mechanism to treat schizophrenia since the 1950s. But there are some downsides to that drug in that it's dosed twice daily as an oral drug, and there's currently no long-acting injectable. And so, twice daily can be difficult for patients with schizophrenia to take. The space is moving towards long-acting injectables, which can last just one injection for several months." "Now, that strategy has been used with other anti-psychotics on the market, such as Invega, to improve their bioavailability and make long-acting forms. So we took that same approach and created the long-acting prodrugs of Cobenfy, which are TerXT, those long-acting prodrugs. We believe that that will enable a once-daily form and a long-acting injectable that can go multiple months from a single injection and thus improve options for patients with schizophrenia." #TerranBio #Prodrug #Antipsychotic #Schizophrenia #MentalHealth terranbiosciences.com Download the transcript here
Dr. Sam Clark, Founder and CEO of Terran Biosciences, is developing a long-acting once-daily formulation of a new class of antipsychotic drugs to treat schizophrenia. The use of a prodrug approach to modify the new drug Cobenfy allows for improved bioavailability and has been shown to have fewer side effects than traditional antipsychotics. This novel class of antipsychotic drugs targets the muscarinic receptor system, which is a different mechanism of action compared to existing treatments. Sam explains, "Schizophrenia is a very severe disease. It has both hallucinations and delusions. It also has a set of symptoms called negative symptoms, which encompass social withdrawal and symptoms that can resemble depressive symptoms, cognitive dysfunction, and memory issues. So, with this patient population, there are a number of drugs that are approved to treat schizophrenia called antipsychotics. But until now, there hasn't been a new drug approved with a new mechanism. So, all drugs have the same mechanism to treat the disease since the 1950s." "But we just got, right now in the space, a new drug approved from Bristol Myers. It just got approved, and Cobenfy is the first new mechanism to treat schizophrenia since the 1950s. But there are some downsides to that drug in that it's dosed twice daily as an oral drug, and there's currently no long-acting injectable. And so, twice daily can be difficult for patients with schizophrenia to take. The space is moving towards long-acting injectables, which can last just one injection for several months." "Now, that strategy has been used with other anti-psychotics on the market, such as Invega, to improve their bioavailability and make long-acting forms. So we took that same approach and created the long-acting prodrugs of Cobenfy, which are TerXT, those long-acting prodrugs. We believe that that will enable a once-daily form and a long-acting injectable that can go multiple months from a single injection and thus improve options for patients with schizophrenia." #TerranBio #Prodrug #Antipsychotic #Schizophrenia #MentalHealth terranbiosciences.com Listen to the podcast here
In this episode, we explore the often-overlooked phenomenon of antipsychotic withdrawal, examining new findings from the world's largest drug safety database. Could some cases of apparent psychotic relapse actually be withdrawal symptoms in disguise? We discuss common withdrawal effects, risk factors, and evidence-based strategies for safe medication discontinuation. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 64 Antipsychotic Withdrawal Syndrome: Symptoms, Risks, and Prevention Strategies
In this episode of Hart2Heart, Dr. Mike Hart sits down with Dr. Josef, a psychiatrist specializing in helping patients safely taper off psychiatric medications. Dr. Josef reveals the devastating truths about the dangers of antidepressants, including the little-known condition of protracted withdrawal, which can cause severe brain damage. Dr. Yosef also discusses the challenges of tapering off these medications and offers practical advice on how to do so safely. He highlights the importance of a slow, flexible taper and the benefits of a paleo diet and regular exercise. Guest Bio and Links: Dr. Josef Witt-Doerring is a board-certified psychiatrist with a specialization in identifying and treating psychiatric adverse drug reactions. He is the founder of The Taper Clinic, which operates in 10 states across the U.S. Dr. Josef and shares his knowledge and experiences to raise awareness about the dangers of psychiatric medications. Learn more about Dr. Josef at his website, on IG @taperclinic, and on YouTube @taperclinic Resources: Surviving Antidepressants Show Notes: (0:00) Welcome back to the Hart2Heart Podcast with Dr. Mike Hart (0:15) Dr. Hart introduces guest, Dr. Josef to the listeners (3:00) Honest critique of psychiatric practices (6:00) Reason Dr. Josef left the pharmaceutical industry (8:00) The reality of protracted withdrawal – a condition most doctors don't recognize (10:00) Which antidepressants are the hardest to quit? (16:30) The safe way to taper off antidepressants (21:00) The issue of sexual dysfunction & antidepressants (25:00) The dangers of antipsychotics - brain shrinkage and movement disorders (26:00) Antipsychotics can shrink your brain 10-15% (28:00) Long-term affects of psychiatric medications (32:30) Psychedelic-assisted therapy (37:30) A natural antidepressant that most people ignore (38:00) Recommended diet while tapering (40:15) Lithium Orotate (5mg) - safe, natural supplement that can help with anxiety (45:30) Most common withdrawal symptoms (48:45) Closing thoughts --- Dr. Mike Hart is a Cannabis Physician and Lifestyle Strategist. In April 2014, Dr. Hart became the first physician in London, Ontario to open a cannabis clinic. While Dr. Hart continues to treat patients at his clinic, his primary focus has shifted to correcting the medical cannabis educational gap that exists in the medical community. Connect on social with Dr. Mike Hart: Social Links: Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
Join us as we talk about Loxapine, an older medication that's stood the test of time and found a niche in psychiatric practice.
Stay up-to-date on the latest advancements in antipsychotic medications and how they're shaping the management of mental health conditions. This episode highlights new formulations, expanded indications, and emerging treatment trends that every pharmacist should know. Don't miss the chance to enhance your expertise and improve patient care! HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTKatelynn Mayberry, PharmDClinical Assistant Professor of Pharmacy PracticeMercer University College of PharmacyREFERENCEThe American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. https://psychiatryonline.org/doi/10.1176/appi.ajp.2020.177901Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Recall recent advancements in antipsychotic medications, including new formulations and expanded therapeutic indications.2. Identify key considerations for pharmacists in optimizing the use of updated antipsychotic treatments to improve patient outcomes.0.05 CEU/0.5 HrUAN: 0107-0000-25-031-H01-PInitial release date: 2/17/2025Expiration date: 2/17/2026Additional CPE details can be found here.
Stay up-to-date on the latest advancements in antipsychotic medications and how they're shaping the management of mental health conditions. This episode highlights new formulations, expanded indications, and emerging treatment trends that every pharmacist should know. Don't miss the chance to enhance your expertise and improve patient care!HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTKatelynn Mayberry, PharmDClinical Assistant Professor of Pharmacy PracticeMercer University College of PharmacyREFERENCEThe American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. https://psychiatryonline.org/doi/10.1176/appi.ajp.2020.177901 Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Recall recent advancements in antipsychotic medications, including new formulations and expanded therapeutic indications.2. Identify key considerations for pharmacists in optimizing the use of updated antipsychotic treatments to improve patient outcomes.0.05 CEU/0.5 HrUAN: 0107-0000-25-031-H01-PInitial release date: 2/17/2025Expiration date: 2/17/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram
Welcome back! Today, we have a special guest-episode with a senior medical student, Jun-Hwan Kim. Join us as we talk about anti-psychotic associated weight gain.
In this episode, we speak with family and long-term care physician Sid Feldman about the KevinMD article "Antipsychotic use has been rising in long-term care homes, but we can do something about it." Sid shares how prescribing rates have surged to 24 percent in Canada, highlights the serious risks of antipsychotic medications, and emphasizes the importance of person-centered strategies. He also provides actionable ideas for addressing pain, encouraging staff education, and refocusing on holistic approaches that promote well-being for older adults living in long-term care. Our presenting sponsor is DAX Copilot by Microsoft. DAX Copilot, by Microsoft, is your AI assistant for automated clinical documentation and workflows. DAX Copilot allows physicians to do more with less and turn their words into a powerful productivity tool. DAX Copilot automates clinical documentation—making it available in the EHR within minutes—and clinical workflows, including referral letters, after-visit summaries, style and formatting customizations, and more. 70 percent of physicians who use DAX Copilot say it improves their work-life balance while reducing feelings of burnout and fatigue. Patients love it too! 93 percent of patients say their physician is more personable and conversational, and 75 percent of physicians say it improves patient experiences. Discover AI-powered solutions for clinical documentation and workflows. Click here to see a 12-minute DAX Copilot demo. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://www.kevinmd.com/cme I'm partnering with Learner+ to offer clinicians access to an AI-powered reflective portfolio that rewards CME/CE credits from meaningful reflections. Find out more: https://www.kevinmd.com/learnerplus
Join us and we discuss a newer anti-psychotic medication, Lumateperone, brand name Caplyta.
In this episode, we explore KarXT, a groundbreaking experimental antipsychotic that works through the cholinergic system rather than dopamine pathways. Could this novel approach revolutionize schizophrenia treatment by offering similar efficacy to current antipsychotics but without the motor side effects? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 63 Xanomeline-Trospium (KarXT) Shows Efficacy in Phase 3 Trial for Schizophrenia
Send Me a Message! In this episode of The Dysregulated Podcast, I explore the vital role Seroquel plays in my ability to get a good night's sleep and how its absence leaves me battling through the day. Sleep deprivation exacerbates the negative ruminations that seem to take centre stage of my psyche, and today, they've been particularly focused on my inner workaholic—the sub-part of me constantly pushing to apply for new jobs and to (hopefully) improve my life! That is one part of me that doesn't slow down, even if the self has! Join me as I do my best to explain the challenges of sleeplessness, self-criticism, and the weight of unrelenting expectations, all before the Seroquel kicks in and I finally get some rest!-Follow my journey living with mental illness and the hard-fought lessons learned along the way. Lived experience is the driving force of this podcast, and through this lens, my stories are told. This is a raw, honest, and authentic account of how multiple psychological disorders have shaped my past and continue to influence my future.Support the showTo support the show, CLICK HEREYou can follow me on Instagram: @elliot.t.waters
Welcome back to our final partial agonist episode! Today we are discussing Cariprazine, brand name, Vraylar.
Welcome back! Brexpiprazole, also known by its brand name Rexulti, is a relatively new medication. Join us for a brief discussion.
Welcome back! Today we are talking about Aripiprazole, brand name Abilify.
In this episode, we explore the RADAR trial's findings on antipsychotic dose reduction in schizophrenia. Can patients with chronic schizophrenia safely reduce or discontinue their antipsychotic medications without increasing relapse risk? The trial's results challenge common assumptions about medication reduction and provide crucial guidance for clinical practice. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 62 Antipsychotic Dose Reduction in Schizophrenia: Insights From the RADAR Trial
Welcome back and Happy New Year! Today, we are kicking it off with a brief episode on Quetiapine (Seroquel).
In this episode, we explore the use of high-dose olanzapine as a potential alternative to clozapine for treatment-resistant schizophrenia. We discuss a systematic review that examines the efficacy and safety of olanzapine doses above the FDA-approved maximum. Could high-dose olanzapine be a viable option when patients refuse clozapine? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 61 Is High-Dose Olanzapine an Option for Treatment-Resistant Schizophrenia?
Welcome back! Today, we have a short-episode on a unique second generation anti-psychotic, Asenapine (Saphris, Secuado).
Susan Grundy is an author who writes about the weight of emotional distress and an easier way of being. Her book, Mad Sisters, is a highly personal account of her caregiving journey for an older sister diagnosed with schizophrenia at the age of 13. When not at her writing desk, Susan can be found walking in nature towards a café. She divides her time between Montreal and London. *** Thank you for being with us to listen to the podcast and read our articles this year. MIA is funded entirely by reader donations. If you value MIA, please help us continue to survive and grow. https://www.madinamerica.com/donate/ To find the Mad in America podcast on your preferred podcast player, click here: https://pod.link/1212789850
In this episode, we explore the cardiac and metabolic safety profile of antipsychotics in youth, based on a World Health Organization Safety Database analysis. We discuss age-dependent risks, specific medication concerns, and the importance of monitoring. How can clinicians balance the benefits of antipsychotics with potential cardiometabolic risks in young patients? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 20 Cardiac and Metabolic Safety Profile of Antipsychotics in Youth
Dr. Larry Wang will be hosting todays episode with a very special guest. . . another Dr. Larry Wang? . . . Bipolar depression being treated with an antidepressant? Welcome to the multiverse.
Welcome back to our antipsychotic series. Today, we will be discussing Olanzapine, brand-name, Zyprexa.
In this episode, we review the high-yield topic of Antipsychotics from the Psychiatry section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets
Dr. Mette Ødegaard Nielsen (Unit for Complicated Schizophrenia, Glostrup, Denmark) joins Dr. Dixon and Dr. Berezin to discuss patient motivations and experiences of antipsychotic medication tapering at a clinic in Denmark. Transcript 01:02 Nielsen interview 02:22 Tapering medication 04:09 Controversies around tapering 07:07 Debilitating effects of side effects 09:09 The tension between medication and side effects for the clinician 12:47 Top line findings 15:28 Psychotic symptom relapse 17:38 Differences by medication 19:43 Expectations from patients 21:47 Shared decision making 24:44 Mixed expectations and reality 27:20 Relapse 29:50 Close contact between patients and clinic staff Subscribe to the podcast here. Check out Editor's Choice, a set of curated collections from the rich resource of articles published in the journal. Sign up to receive notification of new Editor's Choice collections. Browse other articles on our website. Be sure to let your colleagues know about the podcast, and please rate and review it wherever you listen to it. Listen to other podcasts produced by the American Psychiatric Association. Follow the journal on Twitter. E-mail us at psjournal@psych.org
Please visit answersincme.com/DKN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in psychiatry discusses antipsychotics in schizophrenia. Upon completion of this activity, participants should be better able to: Explain the rationale for targeting muscarinic receptors in the treatment of schizophrenia; Describe the clinical implications of evidence on muscarinic receptor agonists in the treatment of schizophrenia; and Outline strategies for optimally incorporating muscarinic receptor agonists into the treatment of patients with schizophrenia.
A new med combo for alcohol use disorder, antipsychotic dose reduction in schizophrenia, and two new tips for using stimulants in ADHD.CME: Take the CME Post-Test for this EpisodePublished On: 10/28/2024Duration: 24 minutes, 12 secondsChris Aiken and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Very few people are willing and/or able to share and describe their descent into psychosis— in part because memory formation and consolidation are so impaired during episodes of psychosis…..and also because there is often so much fear and shame tied up in the experience of losing one's mind. Here Dr. H's patient Corben describes his very early onset illness, how it started with years of depression, then shifted into profound alienation and increasingly frightening psychosis, and finally into stability and recovery.BFTA on IG @backfromtheabysspodcasthttps://www.instagram.com/backfromtheabysspodcast/BFTA/ Dr. Hhttps://www.craigheacockmd.com/podcast-page/
One of the most debilitating aspects of dementia is the behavioral and psychological symptoms of dementia (BPSD) that impact nearly 90% of patients. These symptoms significantly diminish the quality of life and functional abilities of those affected. To combat the most severe of these symptoms, antipsychotic medications are often prescribed, but not without possibly harmful consequences. A new study sheds additional light on these detrimental consequences. Guest Authors: Melissa C. Palmer, PharmD, BCPS, BCPP and Jessa Marie Koch, PharmD, APh, BCPP Music by Good Talk
In this original What the Dementia episode, we will discuss the use of antipsychotic medications for people with Lewy body dementia. This episode will cover: — Risks associated with antipsychotics for Lewy body dementia. — Differences between typical and atypical antipsychotics. — FDA warnings on antipsychotic use in dementia care. — Alternative approaches before considering medication. — Key antipsychotics to avoid and those used with caution. REFERENCES: https://www.lbda.org/treatment-of-behavioral-symptoms-when-to-consider-antipsychotic-medications-in-lbd/ https://pmc.ncbi.nlm.nih.gov/articles/PMC6353494/ Treatment of Lewy Body Dementia by LBDA MENTIONED IN EPISODE: Treehouse | https://letsbambu.com/treehouse List of Antipsychotics | https://letsbambu.link/antipsychotic-list Podcast: Lewy Body Dementia – Those Darn Lewy bodies! | Episode 042 Podcast: Parkinson's Disease Dementia – The 1-Year Rule | Episode 146 Video: 4 Cardinal Symptoms of Dementia with Lewy Bodies CONNECT, GET RESOURCES, LEARN MORE, + SIMPLIFY YOUR CARE JOURNEY: LinkTree | https://www.bambu.care MUSIC CREDIT: Listen To SpillageVillage - Tropical Landing Pop Songs At Looperman.com DISCLAIMER: The information contained in Bambu Care LLC's website, blog, emails, programs, services and/or products is for educational and informational purposes only. While we draw on our prior professional expertise and background in other areas, you acknowledge that we are supporting you in our role exclusively as a Dementia Care Consultant. By participating in Bambu Care, LLC's website, blog, emails, programs, services and/or products, you acknowledge that we are not a licensed psychologist, professional counselor, or medical doctor. We in no way, diagnose, treat, or cure any illnesses or diseases. Dementia Care Consulting is in no way to be construed or substituted as psychological counseling or any other type of therapy or medical advice. The information provided by Bambu Care, LLC also does not constitute legal or financial advice nor is intended to be. Dementia Care Consulting is not a substitute for the services of a CPA or attorney.
KarXT (Cobenfy) is the first antipsychotic that doesn't block dopamine. We trace the origins of this new drug to a South Asian herb used for over 5,000 years, up to the three EMERGENT trials that led to its FDA approval.CME: Take the CME Post-Test for this EpisodePublished On: 10/07/2024Duration: 12 minutes, 28 secondsChris Aiken and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Kennedy Dunn, 3rd year medical student at Howard U and Oyinemi “Yemi” Iyebote discuss how we define what is Ours and what it means to be human in the 6th episode of Stranger Fruit Vol. II Timestamp: 0:00 Exploring Psychiatry and Mental Health 6:55 The Intricacies of Mental Health Disorders 14:07 Embracing Emotions and Overcoming Challenges 23:36 Community Support and Understanding Pain 36:44 Navigating Relationships and Societal Roles Reference: Eaton, W. W., Byrne, M., E. A., & Mors, O. (2008). The epidemiology of psychotic disorders in the community. In J. L. C. & L. W. M. (Eds.), Schizophrenia: Theory, Research, and Therapy (pp. 161-177). Wiley. Hsiao, C. Y., & Kales, H. C. (2018). Antipsychotic use and racial disparities: A review. Journal of the American Geriatrics Society, 66(3), 564-570. Whitfield, E. A., & Williams, D. R. (2017). Racial differences in psychiatric diagnosis and treatment. American Journal of Psychiatry, 174(9), 880-891. Williams, D. R., & Mohammed, S. A. (2009). Discrimination and racial disparities in health: evidence and needed research. Journal of Behavioral Medicine, 32(1), 20-47. Intro Music: Bosch's Garden - by Kjartan Abel. This work is licensed under the following: CC BY-SA 4.0 Attribution-ShareAlike 4.0 International.
Did someone say Latuda Lafooda? Join us as we talk about a frequently used anti-psychotic that recently went generic. Answer to Poll Question Below (SPOILER) ----------------------------------------------------------------- Answer: D (CYP 3A4)
We'd love to hear from you! Send us a text message.In this episode of "Discover Daily," hosts Alex and Sienna explore groundbreaking advancements in medicine, cellular biology, and our understanding of Earth's planetary boundaries. First, they discuss the FDA's approval of Cobenfy, the first new medication for schizophrenia in over three decades. This novel antipsychotic targets cholinergic receptors in the brain, offering a potentially more effective and tolerable treatment option for the millions of adults living with schizophrenia.Next, the hosts dive into the discovery of EndoMac progenitors, a new type of cell found in adult mice that can transform into both blood vessel cells and immune cells. These unique cells show remarkable abilities to enhance wound healing, particularly in conditions like diabetes where healing is often impaired. The discovery of EndoMac progenitors, predicted by scientists over a century ago, could open up exciting new avenues for regenerative medicine and tissue repair.Finally, Alex and Sienna take an in-depth look at the concept of planetary boundaries, the environmental limits within which humanity can safely operate. A recent analysis found that six out of nine of these boundaries have now been crossed, including those for climate change, biodiversity loss, and land-system change. The hosts explain the interconnected nature of these boundaries and discuss the urgent need for transformative action to reduce human impacts on critical Earth systems. They explore the implications for the average person and highlight the importance of understanding these limits for guiding humanity towards a more sustainable future.Perplexity is the fastest and most powerful way to search the web. Perplexity crawls the web and curates the most relevant and up-to-date sources (from academic papers to Reddit threads) to create the perfect response to any question or topic you're interested in. Take the world's knowledge with you anywhere. Available on iOS and Android Join our growing Discord community for the latest updates and exclusive content. Follow us on: Instagram Threads X (Twitter) YouTube Linkedin
On this episode we will be talking about another atypical antipsychotic, Geodon (Ziprasidone). Answer to Poll Question Below (SPOILER) ----------------------------------------------------------------- Answer: C (Akathsia)
In this episode, we explore the use of atypical antipsychotics during pregnancy for women with bipolar disorder. We discuss recent research findings, potential risks, and the delicate balance between managing maternal mental health and fetal safety. How do clinicians approach this challenging clinical decision? Faculty: Vivien Burt, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1 CME: Perinatal Treatment of Bipolar Disorder Risks of Using Antipsychotics During Pregnancy
Join us as we discuss Invega (Paliperidone) and its various long-acting formulations such as Sustenna, Trinza, and Hafyera.
Join us as we discuss a second generation antipsychotic, Risperidone (Risperdal). We will also cover some the long-acting injectable formulations such as Consta, Uzedy and Perseris. Answer to Poll Question Below (SPOILER) ----------------------------------------------------------------- Answer: D (Low-dose Aripiprazole)
Join us as we discuss another typical antipsychotic, Fluphenazine (Prolixin). Answer to Poll Question Below (SPOILER) ----------------------------------------------------------- Answer: B (1.25)
Today, we will be discussing one of the most commonly used first generation anti-psychotics, Haloperidol (Haldol). Answer to Poll Question Below (SPOILER) —————————————————— Answer: Choice C (Fluphenazine) --- Support this podcast: https://podcasters.spotify.com/pod/show/psychrounds/support
Join us as we start off the anti-psychotic series! Today, we will discuss the very first antipsychotic brought to market in the United States, Thorazine (Chlorpromazine). Answer to Poll Question Below (SPOILER) ------------------------------------------------------ Answer: D (Hiccups) --- Support this podcast: https://podcasters.spotify.com/pod/show/psychrounds/support
In this episode, we review the high-yield topic of Antipsychotics from the Psychiatry section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets Linkedin: https://www.linkedin.com/company/medbullets
This week Zorba and Karl look at the health benefits of cold showers, and they discuss new research focusing on the potential harms of antipsychotic medicines. Plus, they share a […]
VISIT US AT NCLEXHIGHYIELD.COM No matter where you are in the world, or what your schedule is like, access the entire course at www.NCLEXHighYieldCourse.com The NCLEX High Yield Podcast was featured on Top 15 NCLEX Podcasts! Make sure you JOIN OUR NEW VIP FACEBOOK GROUP! https://nclexhighyield.com/blogs/news/nclex-high-yield-quick-links A topic that confuses many, but listen to how Dr. Zeeshan breaks this bad boy down! Many people get overwhelmed with all the information that's out there, we keep it simple! Join us weekly for FREE Zoom Sessions and be one of the many REPEAT test takers that passed the exam by spending NO MONEY with NCLEX High Yield! NCLEX High Yield is a Prep Course and Tutoring Company started by Dr. Zeeshan in order to help people pass the NCLEX, whether it's the first time , or like the majority of our students, it's NOT their first time. We keep things simple, show you trends and tips that no one has discovered, and help you on all levels of the exam! Follow us on Instagram: @NCLEXHighYield or check out our website www.NCLEXHighYield.com Make sure you join us for our FREE Weekly Zoom Sessions! Every Wednesday 3PM PST / 6PM EST. Subscribe to our newsletter at nclexhighyield.com --- Support this podcast: https://podcasters.spotify.com/pod/show/nclexhighyield/support
© 2020-2025 Ivy Podcast Discovery LLC
